降压药物依从性与APOE基因型及后续痴呆风险
在控制血压等因素后,持续坚持服用降压药的高血压患者痴呆风险比低依从组低27%(HR 0.73,95%CI 0.61-0.87),高依从组与正常血压组风险差异无统计学意义。
要点
- 持续坚持服用降压药与后续痴呆风险降低27%相关(HR 0.73,95%CI 0.61-0.87)。
- 高依从组与正常血压组的痴呆风险无显著差异(HR 1.03,95%CI 0.88-1.21)。
- APOE ε4携带状态未显著改变依从性与痴呆风险的关联(交互P=0.939)。
核心结论
- 在社区居住的中老年人群中,持续坚持服用降压药物与后续痴呆风险降低相关。
研究设计与样本
- 纵向队列研究,使用健康与退休研究第8波(2006年)至第14波(2018年)的12年调查数据。
- 采用Cox比例风险回归评估痴呆风险,计算调整后风险比(HR)和95%置信区间(CI)。
主要发现
- 在控制血压和其他已知风险因素后,持续坚持服用降压药的高血压患者痴呆风险比低依从组低27%(HR 0.73,95%CI 0.61-0.87)。
- 高依从组与正常血压组相比,痴呆风险差异无统计学意义(HR 1.03,95%CI 0.88-1.21)。
- 在非APOE ε4携带者中HR为0.73(95%CI 0.59-0.89),在APOE ε4携带者中HR为0.75(95%CI 0.55-1.02),交互作用P值为0.939。
临床怎么用
- 对于社区居住的中老年高血压患者,应强调持续坚持服用降压药物,以可能降低后续痴呆风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aim to examine prospective associations of longitudinal adherence to antihypertensive medication, APOE ε4 carrier, and subsequent dementia risk in community-dwelling middle-aged and older adults. METHODS: A longitudinal cohort using 12-year survey data from wave 8 (2006) to wave 14 (2018) in the Health and Retirement Study, an ongoing national survey recruiting community-dwelling adults aged ≥50 years in the United States. Longitudinal adherence to antihypertensive medication was evaluated during wave 8 (2006) to wave 10 (2010), based on self-reported antihypertensive medication use at each wave. Incident dementia cases were ascertained during wave 10 (2010) to wave 14 (2018) by combining self-reported diagnosis and standardized cognitive batteries, excluding prevalent cases during the medication adherence evaluation period. Cox proportional hazard regression was utilized to assess dementia risk, with adjusted hazard ratios (HR) and 95% CIs calculated, controlling for sociodemographic characteristics, socioeconomic status indicators, lifestyle factors, and clinical conditions, as well as blood pressure measurements. RESULTS: A total of 18 469 participants were screened, after which 11 835 participants (mean [SD] age: 66.2 [10.1] years; men: 40.6%) were included, with 1136 incident dementia cases. After controlling blood pressure and other known risk factors, hypertension participants who persistently adhered to antihypertensive medication during follow-up had a 27% lower dementia risk (HR, 0.73 [95% CI, 0.61-0.87]) than the low adherence group, which was more evident than the associations between baseline antihypertensive medication use and dementia. The difference in dementia risk was insignificant when comparing the high adherence group with the normotension group (HR, 1.03 [95% CI, 0.88-1.21]). The results were consistent in non-APOE ε4 carriers (HR, 0.73 [95% CI, 0.59-0.89]) versus APOE ε4 carriers (HR, 0.75 [95% CI, 0.55-1.02]; P for interaction: 0.939). CONCLUSIONS: Persistently adhering to antihypertensive medication was consistently associated with a lower subsequent dementia risk in community-dwelling middle-aged and older adults.
引用
- Li Y, Li C. Antihypertensive Medication Adherence, APOE Genotype, and Subsequent Dementia in Community-Dwelling Adults ≥50 Years. Stroke. 2025. PMID: 41439317. doi:10.1161/STROKEAHA.125.051564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。